Mylan revises earnings guidance, defers product launches to 2018

Mylan NV on Wednesday said it is deferring all major U.S. launches from its full-year 2017 financial guidance to 2018, citing ongoing challenges and the uncertain U.S. regulatory environment. As a result, the pharmaceutical giant expects to deliver total revenues ranging between $11.5 billion and $12.5 billion and adjusted earnigns per share between $4.30 and $4.70. The product launches include generic versions of Advair and Copaxone. Mylan (Nasdaq:MYL) included the announcement in its quarterly…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news